新生儿缺氧缺血性脑病患儿重组人促红细胞生成素治疗前后心肌酶变化的研究

目的分析新生儿缺氧缺血性脑病(HIE)患儿使用重组人促红细胞生成素(rhEPO)治疗前后心肌酶变化的临床意义。方法 110例HIE患儿,随机分为治疗组(n=55)及对照组(n=55),治疗组予rhEPO治疗,对照组给予常规治疗,分别于生后24h、7d、14d对新生儿治疗前后进行血清肌酸激酶(CK)及肌酸激酶同工酶(CK-MB)的检测。结果治疗组治疗7d、14d后心肌酶下降较对照组治疗7d、14d后下降显著。结论 rhEPO治疗新生儿HIE可使心肌酶明显下降,心肌酶谱是HIE治疗的指标之一,说明了rhEPO治疗新生儿HIE是有效的。HIE患儿CK及CK-MB的变化对于判断病情、估计预后、指导治疗具有重要的临床意义。

The fluctuation of cardiac enzyme in neonatal hypoxic-ischemic encephalopathy with recombinant human erythropoietin treatment

Objective To evaluate the cardiac enzyme changes in neonates with hypoxic-ischemic encephalopathy （HIE） before and after treatment with recombinant human erythropoietin （rhEPO）. Methods A total of 110 neonates with HIE were randomly divided into a treated group （ n =55） and a control group （ n = 55）. The treated group received rhEPO while the control group received conventional therapy. Before and after treatment, creatine kinase and creatine kinase-MB were monitored at 24 h, day7 and dayl4 after delivery. Results Cardiac enzymes was significantly lower at day7 and day14 after delivery in the treated group than control group. Conclusion Neonatal HIE with rhEPO treatment can downregulate cardiac enzyme, and cardiac enzyme is one of the indexes for HIE treatment. The results suggest that rhEPO is effective for HIE infants. Furthermore, CK and CK-MB are important markers in diagnosis, predicting prognosis and guiding treatment for HIE neonates.